Brief: Eliem Provides Update On ETX-810 And ETX-155 Clinical Programs

Climb Bio

25/04/2022 12:14

April 25 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM PROVIDES UPDATE ON ETX-810 AND ETX-155 CLINICAL PROGRAMS
    * ELIEM THERAPEUTICS INC - PHASE 2A CLINICAL TRIAL OF ETX-810 IN DIABETIC
PERIPHERAL NEUROPATHIC PAIN (DPNP) DID NOT ACHIEVE PRIMARY ENDPOINT
    * ELIEM THERAPEUTICS INC - ENROLLMENT OF ETX-155 PHASE 2A CLINICAL TRIALS IN
DEPRESSION DELAYED F
    * ELIEM THERAPEUTICS INC - PHASE 2A CLINICAL TRIAL EVALUATING ETX-810 IN
PATIENTS
WITH LUMBOSACRAL RADICULAR PAIN (LSRP) HAS BEEN FULLY ENROLLED
    * ELIEM THERAPEUTICS INC - WELL CAPITALIZED TO FUND COMPANY THROUGH MULTIPLE
ADDITIONAL CATALYSTS ACROSS PIPELINE
    * ELIEM THERAPEUTICS INC - NEXT QUARTER, WE ANTICIPATE READ OUT OF TOPLINE
PHASE
2A DATA FOR ETX-810 IN LSRP

Source text for Eikon:  ID:nGNX83dGtS 
Further company coverage:  ELYM.O 

 ((Reuters.Briefs@thomsonreuters.com;))